Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$56.44
pos +0.00
+0.00%
Today's Range: 55.88 - 56.47 | BMY Avg Daily Volume: 12,669,600
Last Update: 02/24/17 - 4:00 PM EST
Volume: 0
YTD Performance: -4.57%
Open: $0.00
Previous Close: $55.77
52 Week Range: $46.01 - $77.12
Oustanding Shares: 1,672,715,340
Market Cap: 93,287,334,512
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 6 6
Moderate Buy 1 1 1 1
Hold 5 7 9 9
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.27 2.35 2.50 2.50
Latest Dividend: 0.39
Latest Dividend Yield: 2.80%
Dividend Ex-Date: 01/04/17
Price Earnings Ratio: 21.05
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
21.05 21.00 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.73% -9.07% 3.01%
GROWTH 12 Mo 3 Yr CAGR
Revenue 4.30 0.20 0.06
Net Income 166.70 0.80 0.20
EPS 174.00 0.70 0.19
Earnings for BMY:
EBITDA 4.63B
Revenue 19.43B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.74 $0.69 $2.79 $3.07
Number of Analysts 5 5 10 9
High Estimate $0.78 $0.72 $2.87 $3.60
Low Estimate $0.69 $0.66 $2.69 $2.64
Prior Year $0.74 $0.69 $2.83 $2.79
Growth Rate (Year over Year) -0.54% -0.58% -1.45% 10.08%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Cramer

 | Feb 24, 2017 | 6:08 AM EST
You have to keep up with the sector rotations.
RMPIA
By

Doug Kass

 | Feb 22, 2017 | 5:07 PM EST
"Bull markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria." -- Sir John Templeton 
RMPIA
By

Jim Cramer

 | Feb 22, 2017 | 1:57 PM EST
These may be uncharted waters, but they're not necessarily expensive.
RMPIA
By

Jim Cramer

 | Feb 22, 2017 | 11:45 AM EST
Icahn may have a tough time finding interest in this behemoth.
RMPIA
By

Doug Kass

 | Feb 21, 2017 | 2:55 PM EST
 
RMPIA
By

Bret Jensen

 | Feb 20, 2017 | 10:00 AM EST
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
RMPIA
By

Bret Jensen

 | Feb 17, 2017 | 1:00 PM EST
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
RMPIA
By

Bruce Kamich

 | Feb 16, 2017 | 11:18 AM EST
You might want to review your holdings in the sector.
RMPIA
By

Doug Kass

 | Feb 15, 2017 | 3:49 PM EST
I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. 
RMPIA
By

Bret Jensen

 | Feb 15, 2017 | 11:30 AM EST
M&A activity is in a serious upswing, and here are some names to watch.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.